Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
The recent move by the U.S. government to negotiate Medicare drug prices has triggered speculation about which drugs could be targeted in the next round of negotiations, which is set for 2027.
美國政府最近談判醫療保險藥品價格的舉措引發了關於下一輪談判可能針對哪些藥品的猜測，該輪談判定於2027年進行。
Last week, the Biden administration announced that Medicare's newly negotiated prescription drug prices are expected to save the U.S. government $6 billion in the first year alone.
上週，拜登政府宣佈，醫療保險新談判藥品價格預計僅在第一年就能爲美國政府節省60億美元。
According to some analysts, Novo Nordisk A/S' (NYSE:NVO) blockbuster diabetes drug Ozempic might be included, along with several other well-known medications.
據一些分析師稱，諾和諾德（Novo Nordisk A/S）的糖尿病療法明星藥物奧塞皮（Ozempic）可能會被納入，以及其他幾種知名藥物。
Also Read: Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy.
另外閱讀：諾和諾德Wegovy對心臟病患者的醫療保險覆蓋存在困難。
These could include Pfizer Inc.'s (NYSE:PFE) cancer drugs Ibrance and Xtandi, GSK Plc's (NYSE:GSK) asthma treatment Trelegy Ellipta, Teva Pharmaceutical Industries Ltd.'s (NYSE:TEVA) Huntington's disease drug Austedo, and Abbvie Inc.'s (NYSE:ABBV) irritable bowel syndrome treatment Linzess.
這些藥品可能包括輝瑞公司的癌症藥物Ibrance和Xtandi，葛蘭素史克公司（GSK）的哮喘治療藥物Trelegy Ellipta，梯瓦製藥公司的亨廷頓病藥物Austedo，以及艾伯維公司的腸易激綜合徵治療藥物Linzess。
The list would focus on drugs available since at least 2017, primarily those on which Medicare spends heavily.
該名單將重點關注至少自2017年以來可獲得的藥物，主要是醫療保險支出較大的藥物。
Under President Joe Biden's Inflation Reduction Act (IRA), the prices of 10 popular Medicare drugs will be reduced by up to 79% in 2026.
根據喬·拜登總統的通脹減少法案（IRA），2026年將減少10種熱門醫療保險藥物的價格高達79%。
This move has faced resistance from the pharmaceutical industry, which argues that such measures could stifle innovation. Government officials, however, maintain their commitment to reducing healthcare costs.
這一舉措遭到了藥品行業的抵制，他們認爲此類措施可能會扼殺創新。然而，政府官員堅持承諾降低醫療保健費用。
Despite concerns about the impact on pharmaceutical companies, a Reuters report suggests the financial blow might be less severe than anticipated.
儘管對藥品公司的影響存在擔憂，路透社的一份報告表明，財務打擊可能會比預期的要輕。
Company executives appear to be cautiously optimistic. Pfizer's Chief U.S. Commercial Officer, Aamir Malik, stated that the timing of patent expirations for Ibrance and Xtandi could allow the company to manage the price negotiations effectively.
公司高管似乎持謹慎樂觀態度。輝瑞公司美國首席商業官Aamir Malik表示，Ibrance和Xtandi專利到期的時機可能使公司能夠有效地處理價格談判。
Similarly, Teva CEO Richard Francis acknowledged the potential impact of price cuts but remained confident in Austedo's growth prospects, forecasting $2.5 billion in earnings by 2027.
同樣，梯瓦製藥CEO Richard Francis承認價格下調的潛在影響，但對Austedo的增長前景保持信心，預計到2027年收入將達250億美元。
Abbvie's CEO expressed a similar sentiment, indicating that their long-term outlook remains intact, even considering future negotiations.
艾伯維公司的CEO表達了類似的看法，表示他們的長期展望仍然完好，甚至考慮未來的談判。
Regulators will announce up to 15 more drugs for negotiation in 2028, potentially expanding the scope to include medications covered under Medicare's Part B program.
監管機構將在2028年宣佈多達15種藥品進行談判，有可能擴大範圍以包括醫療保險Medicare的B部分計劃下的藥物。
As drug negotiations progress, the Congressional Budget Office estimates that savings from the IRA will rise to $9.4 billion by 2027, marking a significant step in the government's effort to reduce healthcare costs.
隨着藥品談判的推進，國會預算辦公室估計，到2027年，從IRA中的節省將上升到940億美元，這標誌着政府減少醫療成本的重大一步。
Price Action: NVO stock is down 0.64% at $136 at last check Friday.
股價走勢：NVO股價在最近一次檢查時下跌0.64%，報136美元。週五。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
- 爲什麼診斷測試供應商applied dna sciences股票週五交易更高？
Image By Natalia Varlei On Shutterstock
圖片來自Natalia Varlei的Shutterstock
